ERLOTINIB

作品数：97被引量：249H指数：7
导出分析报告
相关作者：周田彦卢炜吴煜农黄顺张晓菊更多>>
相关机构：南京医科大学广东省人民医院中山大学北京大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金广东省科技计划工业攻关项目广东省医学科学技术研究基金天津市自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Three-in-one erlotinib-modified NIR photosensitizer for fluorescence imaging and synergistic chemo-photodynamic therapy
《Chinese Chemical Letters》2025年第2期295-299,共5页Du Liu Yuyan Li Hankun Zhang Benhua Wang Chaoyi Yao Minhuan Lan Zhanhong Yang Xiangzhi Song 
supported by the National Natural Science Foundation of China(Nos.22278447 and 22178395);State Key Laboratory of Fine Chemicals(No.KF2109);State Key Laboratory of Chemo/Biosensing and Chemometrics(No.20230768)。
Photodynamic therapy(PDT)presents a promising avenue in cancer treatment.Erlotinib,an FDAapproved anticancer drug targeting epidermal growth factor receptor(EGFR),has shown effectiveness in normalizing tumor vasculatu...
关键词：PHOTOSENSITIZER Benzo[a]phenoselenazinium Fluorescence imaging Photodynamic therapy Chemotherapy 
Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway被引量：1
《International Journal of Ophthalmology(English edition)》2024年第6期1018-1027,共10页Yu-Sheng Zhu Si-Rui Zhou Hui-Hui Zhang Tong Wang Xiao-Dong Chen 
Supported by the Natural Science Foundation of Shaanxi Province,China(No.2022JM-521).
AIM:To explore the effect of epidermal growth factor receptor(EGFR)inhibition by erlotinib and EGFR siRNA on epidermal growth factor(EGF)-induced activation of retinal pigment epithelium(RPE)cells.METHODS:Human RPE ce...
关键词：ERLOTINIB epidermal growth factor receptor protein kinase B epithelial-mesenchymal transition retinal pigment epithelium cell 
Multistep continuous flow synthesis of Erlotinib被引量：1
《Chinese Chemical Letters》2024年第4期371-375,共5页Hui Jin Qin Cai Peiwen Liu Yan Chen Derong Wang Weiping Zhu Yufang Xu Xuhong Qian 
the National Natural Science Foundation of China(Nos.21878088, 21476077);Key Projects of Shanghai Science and Technology Commission (No.18DZ1112703) for financial support。
Erlotinib is an orally administered, highly effective, specific epidermal growth factor receptor tyrosine kinase inhibitor, used to treat non-small cell lung cancer and pancreatic cancer. The traditional synthetic met...
关键词：ERLOTINIB Continuous flow synthesis Microchannel flow reactor Process optimization Continuous nitration Continuous hydrogenation 
Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer:A meta-analysis
《World Journal of Gastrointestinal Surgery》2024年第3期921-931,共11页Xiao-Yan Liu Hong-Nian Pan Yue Yu 
Supported by National Natural Science Foundation of China,No.31870993;Fundamental Research Funds for the Central Universities,No.WK9110000005;Anhui Provincial Health Research Project,No.AHWJ2022c020;Anhui Medical University Campus Level Research Fund,No.2020xkj229;Lu'an City Science and Technology Plan Project,No.2022Lakj009;New Technology and Project of Lu'an People's Hospital,No.2021xjs10.
BACKGROUND Advanced pancreatic cancer is resistant to chemotherapeutic drugs,resulting in limited treatment efficacy and poor prognosis.Combined administration of the chemotherapeutic gemcitabine and erlotinib is cons...
关键词：ERLOTINIB CHEMOTHERAPY Advanced pancreatic cancer EFFICACY Safety META-ANALYSIS 
Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival被引量：2
《World Journal of Gastroenterology》2024年第7期714-726,共13页Pui-Yin Leung Wenjing Chen Anissa N Sari Poojitha Sitaram Pui-Kei Wu Susan Tsai Jong-In Park 
Supported by NIH/National Cancer Institute Grant,No.R01CA138441 and No.R01CA269452;UW Madison Centene Pancreas Cancer Collaborative Award,No.21-8568.
BACKGROUND Pancreatic cancer is a leading cause of cancer-related deaths.Increased activity of the epidermal growth factor receptor(EGFR)is often observed in pancreatic cancer,and the small molecule EGFR inhibitor erl...
关键词：Pancreatic cancer ERLOTINIB Mitochondria-targeted ubiquinone Mitochondria Combination therapy 
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer:final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial被引量：11
《Signal Transduction and Targeted Therapy》2023年第3期1310-1317,共8页Wen-Zhao Zhong Hong-Hong Yan Ke-Neng Chen Chun Chen Chun-Dong Gu Jun Wang Xue-Ning Yang Wei-Min Mao Qun Wang Gui-Bin Qiao Ying Cheng Lin Xu Chang-Li Wang Ming-Wei Chen Xiao-Zheng Kang Wan-Pu Yan Ri-Qiang Liao Jin-Ji Yang Xu-Chao Zhang Si-Yang Liu Qing Zhou Yi-Long Wu 
The authors thank all patients and their families.The authors would like to acknowledge the editorial support provided by Keyra Martinez Dunn,MD,of Edanz(www.edanz.com),which was funded by Shanghai Roche Pharmaceutical Ltd.This study was funded by the Chinese Thoracic Oncology Group(CTONG),Shanghai Roche Pharmaceutical Ltd.
EMERGING-CTONG 1103 showed improved progression-free survival(PFS)with neoadjuvant erlotinib vs.chemotherapy for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer(...
关键词：NEOADJUVANT CISPLATIN chemotherapy 
Peripheral corneal ulcer secondary to acquired eyelash trichomegaly following treatment with erlotinib in Asia:a case report
《International Journal of Ophthalmology(English edition)》2023年第3期468-469,共2页Kin-Man Tam Iat-Fan Lai 
Dear Editor,Erlotinib is an epidermal growth factor receptor (EGFR)inhibitor used in the treatment of non-small cell lung cancer.Common side effects of erlotinib include rash and diarrhea,while eyelash trichomegaly an...
关键词：DIARRHEA TREATMENT ULCER 
Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report
《The Journal of Biomedical Research》2022年第6期440-445,共6页Mingzi Zhang Qi Li Yehong Sun 
Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)plays an important role in cancer therapy.However,EGFR is highly expressed in the skin and gives rise to one of the most concerning issues for the EG...
关键词：epidermal growth factor receptor tyrosine kinase inhibitor skin rash Pien Tze Huang ERLOTINIB 
Pharmacological drug screening to inhibit uveal melanoma metastatic cells either via EGF-R, MAPK, mTOR or PI3K被引量：1
《International Journal of Ophthalmology(English edition)》2022年第10期1569-1576,共8页Stefan Kassumeh Sebastian Arrow AndréKafka Nikolaus Luft Siegfried G.Priglinger Armin Wolf Kirsten Eibl-Lindner Christian M.Wertheimer 
AIM: To screen five potential pharmacological substances specifically targeting EGF-R, MAPK, mTOR, or PI3K for their antiproliferative effects, possible impact on cell viability, as well as cell death rates on three d...
关键词：uveal melanoma SELUMETINIB trametinib erufosine ERLOTINIB 
A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
《Bioactive Materials》2022年第7期312-323,共12页Duo Wang Jun Zhou Weimin Fang Cuiqing Huang Zerong Chen Meng Fan Ming-Rong Zhang Zeyu Xiao Kuan Hu Liangping Luo 
This study was supported partly by grants from the Natural Science Foundation of China(81771973,81971672 and 82102005);Key Program of the Natural Science Foundation of Guangdong Province(2018B0303110011);Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation(201905010003);Fundamental Research Funds for the Central Universities(21620308 and 21620101);JSPS KAKENHI grant Nos.21H02873,21K07659,and 20H03635;the AMED Moonshot Research and Development Program(Grant No 21zf0127003h001).
Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKI),such as Erlotinib,have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer(NSCLC)patients with mutated EGFR.However,the...
关键词：Non-small cell lung cancer EGFR wild-Type Superparamagnetic iron oxide ERLOTINIB BEVACIZUMAB Tumour vascular normalization 
全选清除导出
共10页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部